Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases
…, I Levy, Y Yavne, M Yavzori, O Picard, E Fudim… - Clinical …, 2016 - Elsevier
Background & Aims It is not clear what serum levels of anti–tumor necrosis factor are associated
with reduced intestinal inflammation in patients with inflammatory bowel disease (IBD). …
with reduced intestinal inflammation in patients with inflammatory bowel disease (IBD). …
Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel …
…, U Kopylov, M Yavzori, O Picard, E Fudim… - Clinical …, 2013 - Elsevier
There are few therapeutic options for patients with inflammatory bowel disease who lose
response to infliximab because they produced antibodies against the drug. We performed a …
response to infliximab because they produced antibodies against the drug. We performed a …
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
B Ungar, Y Chowers, M Yavzori, O Picard, E Fudim… - Gut, 2014 - gut.bmj.com
Objective To characterise the temporal evolution of antibodies to infliximab (ATI). Design
Prospective observational study of infliximab-treated patients with inflammatory bowel disease …
Prospective observational study of infliximab-treated patients with inflammatory bowel disease …
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
S Ben-Horin, M Yavzori, I Benhar, E Fudim, O Picard… - Gut, 2016 - gut.bmj.com
Objective The cross-immunogenicity of the recently approved infliximab-biosimilar Remsima
(CT-P13) with the originator drug Remicade is still unknown. Design Sera of patients with …
(CT-P13) with the originator drug Remicade is still unknown. Design Sera of patients with …
The immunogenic part of infliximab is the F (ab′) 2, but measuring antibodies to the intact infliximab molecule is more clinically useful
…, M Yavzori, L Katz, U Kopylov, O Picard, E Fudim… - Gut, 2011 - gut.bmj.com
Objectives To localise the immunogenic part of infliximab and evaluate the clinical usefulness
of measuring antibodies against infliximab fragments. Design Observational study. …
of measuring antibodies against infliximab fragments. Design Observational study. …
Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease
…, U Kopylov, O Picard, E Fudim… - Journal of Crohn's …, 2011 - academic.oup.com
Introduction: Limited data suggest the absence of infliximab in breast milk, thereby implying
the safety of this drug during breast-feeding. We aimed to re-evaluate the presence of …
the safety of this drug during breast-feeding. We aimed to re-evaluate the presence of …
Association of vedolizumab level, anti-drug antibodies, and α4β7 occupancy with response in patients with inflammatory bowel diseases
B Ungar, U Kopylov, M Yavzori, E Fudim… - Clinical …, 2018 - Elsevier
Background & Aims There are few data available on the real-life pharmacokinetic and
pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We …
pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We …
Adalimumab level in breast milk of a nursing mother
…, M Yavzori, L Katz, O Picard, E Fudim… - Clinical …, 2010 - cghjournal.org
Dear Editor: The safety of the anti-tumor necrosis factor (TNF)-α antibody adalimumab in
nursing mothers is unknown, and studies of its excretion into breast milk are lacking. 1 We …
nursing mothers is unknown, and studies of its excretion into breast milk are lacking. 1 We …
Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab …
U Kopylov, Y Mazor, M Yavzori, E Fudim… - Inflammatory bowel …, 2012 - academic.oup.com
Background Anti-infliximab antibodies (ATIs) are associated with lower serum infliximab (IFX)
trough levels and diminished clinical response. The current most prevalent method for …
trough levels and diminished clinical response. The current most prevalent method for …
Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the POETIC study
…, OH Natour, M Yavzori, E Fudim… - Official journal of the …, 2018 - journals.lww.com
OBJECTIVES: Adalimumab is usually self-injected at home, making prospective serial-sampling
studies challenging and scarce. This has led to a gap in knowledge about evolution of …
studies challenging and scarce. This has led to a gap in knowledge about evolution of …
In response to a complaint we received under the US Digital Millennium Copyright Act, we have removed 1 result(s) from this page. If you wish, you may read the DMCA complaint that caused the removal(s) at LumenDatabase.org.